Cellvizio

Mauna Kea Technologies is a global medical device company that develops and markets Cellvizio, the world's first and only real-time in vivo cellular imaging platform. Utilizing probe-based and needle-based confocal laser endomicroscopy (pCLE/nCLE), the technology allows physicians to visualize tissues at the cellular level during standard endoscopic procedures, effectively performing "optical biopsies." The platform is used across multiple specialties, including gastroenterology, pulmonology, and urology, to improve the diagnosis and management of conditions such as cancer, pancreatic cysts, and food intolerances. Headquartered in Paris with a significant presence in the United States, the company is publicly traded and partners with major healthcare leaders to integrate its imaging technology into robotic surgery and molecular-guided interventions.